Posted by Michael Wonder on 13 Apr 2022
BriaCell receives FDA fast track approval for targeted breast cancer immunotherapy
13 April 2022 BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with fast track designation.
BriaCell Therapeutics announces that the U.S. FDA has granted fast track status to BriaCell’s lead candidate, Bria-IMT, for the treatment of metastatic breast cancer.
